CTSG-expressing mast cells confer resistance to immunotherapy in colorectal cancer - Takeaways - MDSpire

CTSG-expressing mast cells confer resistance to immunotherapy in colorectal cancer

  • By

  • Xuehui Jiang

  • Runsheng Hong

  • Zilin Liu

  • Chao Zhong

  • Yun Dai

  • July 1, 2026

  • 0 min

Share

  • 1

    Mast cells in colorectal cancer (CRC) exhibit altered transcriptional states and are associated with tumor molecular features.

  • 2

    A specific subset of mast cells expressing cathepsin G (CTSG) correlates with immunotherapy resistance and poor prognosis in CRC patients.

  • 3

    Mast cell deficiency reduces tumor growth and increases immune cell infiltration in a murine orthotopic CRC model.

  • 4

    CTSG from mast cells promotes tumor metabolic adaptation and limits CD8+ T cell recruitment in the tumor microenvironment.

  • 5

    Pharmacological inhibition of CTSG enhances CD8+ T cell function and improves the efficacy of anti-PD-1 therapy in CRC.

Original Source(s)

CTSG-expressing mast cells confer resistance to immunotherapy in colorectal cancer

  • by Xuehui Jiang, Runsheng Hong, Zilin Liu, Chao Zhong, Yun Dai

  • July 1, 2026

Related Content

Bifidobacterium infantis-mediated HSV-TK/GCV therapy modulates the tumor microenvironment through site-specific phosphorylation of HIF-1α, mTOR, and PD-L1

Development and expert radiologist validation of a custom pipeline for simplification of oncology radiology reports using large language model

Next-generation CAR-T engineering for colorectal cancer: integrating targets, tumor microenvironment barriers, and emerging strategies